Hidroxizina Bluefish

Hidroxizina Bluefish is a prescription medication that contains the active ingredient hydroxyzine hydrochloride, supplied in an oral dosage form. It belongs to the first‑generation H1 antihistamine class and is marketed in the European Union. The product is intended for systemic use under medical supervision and is not available over the counter. Hydroxyzine hydrochloride provides antihistaminic, anxiolytic, and sedative effects through central and peripheral H1 receptor blockade.

Hidroxizina Bluefish is prescribed for several conditions that involve histamine‑mediated symptoms or require pre‑operative calming.

- Relief of allergic dermatitis and other skin itching conditions. - Management of generalized pruritus associated with hepatic, renal or dermatologic disorders. - Short‑term treatment of anxiety or tension when a sedating antihistamine is appropriate. - Pre‑operative sedation to reduce anxiety and produce mild tranquilization before surgery. - Prevention of nausea and vomiting related to anesthesia or motion sickness.

Like other first‑generation antihistamines, hydroxyzine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common: - Drowsiness or sedation. - Dry mouth, throat, or nasal passages. - Blurred vision or difficulty focusing. - Constipation or reduced gastrointestinal motility. - Headache or mild dizziness. - Nausea or mild gastrointestinal upset. - Transient feeling of warmth or flushing.

Serious: - Severe allergic reaction (anaphylaxis) with rash, swelling, or difficulty breathing. - Cardiac arrhythmias or prolonged QT interval. - Hepatotoxicity presenting as jaundice or elevated liver enzymes. - Extrapyramidal symptoms such as tremor or rigidity. - Significant confusion or delirium, especially in elderly patients. - Seizures in patients with pre‑existing neurological disorders.

When prescribing Hidroxizina Bluefish, clinicians should evaluate patient history and monitor for conditions that could increase the risk of adverse effects.

- Avoid use in patients with known hypersensitivity to hydroxyzine or other first‑generation antihistamines. - Use cautiously in the elderly, who may experience enhanced sedation and confusion. - Do not combine with alcohol, central nervous system depressants, or other sedating agents. - Assess liver and kidney function before initiating therapy, as impairment may alter drug clearance. - Monitor for cardiac conduction abnormalities, especially in patients taking other QT‑prolonging drugs. - Pregnant or breastfeeding women should only use the medication when the potential benefit outweighs risk.

Hydroxyzine can interact with several medications, altering its sedative effect or cardiac safety profile.

Avoid: - Concurrent use with other antihistamines or sedating antihistamines. - Combination with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI. - Co‑administration with potent CYP3A4 inhibitors such as ketoconazole or erythromycin.

Use with caution: - Alcohol or CNS depressants (opioids, benzodiazepines, barbiturates) may increase sedation. - Drugs that prolong the QT interval (e.g., certain antiarrhythmics, fluoroquinolones) should be used with caution. - Anticholinergic agents (e.g., tricyclic antidepressants, antipsychotics) may enhance anticholinergic side effects. - Medications cleared renally (e.g., digoxin) may require dose adjustment in renal impairment.